SAN DIEGO, July 28, 2017 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will report second quarter 2017 results after the Nasdaq market
close on August 3, 2017.
Neurocrine will then host a live conference call and webcast
to discuss its financial results and provide a Company update that
day at 5:00pm Eastern Time
(2:00pm Pacific Time).
Participants can access the live conference call by dialing
888-632-3381 (US) or 785-424-1678 (International) using the
conference ID: NBIX. The call can also be accessed via the webcast
through the Company's website at http://www.neurocrine.com.
If you are unable to attend the webcast and would like further
information on this announcement, please contact the Investor
Relations Department at ir@neurocrine.com. A replay of the
conference call will be available approximately one hour after the
conclusion of the call by dialing 800-243-8160 (US) or 402-220-9032
(International) using the conference ID: NBIX. The call will be
archived for one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a San
Diego based biotechnology company focused on neurologic,
psychiatric and endocrine related disorders. In April of 2017, the
FDA approved INGREZZA® (valbenazine) capsules for the treatment of
adults with tardive dyskinesia (TD). INGREZZA is a novel,
selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and
is the first and only FDA-approved product indicated for the
treatment of adults with TD. The Company markets INGREZZA in
the United States. The Company's
three late-stage clinical programs are: elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc.; opicapone, a novel, once-daily,
peripherally-acting, highly-selective catechol-o-methyltransferase
inhibitor under investigation as adjunct therapy to levodopa in
Parkinson's patients; and INGREZZA (valbenazine), a novel,
once-daily, selective VMAT2 inhibitor under investigation for the
treatment of Tourette syndrome.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
View original
content:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-second-quarter-2017-results-300495827.html
SOURCE Neurocrine Biosciences, Inc.